Last updated: October 6, 2026
DUAC is a mature fixed-dose topical acne medicine combining clindamycin phosphate 1.2% with benzoyl peroxide 5%. Its commercial position is defined by generic competition, limited brand-level disclosure, and declining value from antibiotic-containing acne treatments. The original product’s regulatory and patent protections no longer create a meaningful global exclusivity barrier. Revenue is likely concentrated in established prescription markets where Duac retains physician recognition, reimbursement access, or brand preference.
What is DUAC and how is it positioned in acne treatment?
DUAC is a once-daily topical gel for acne vulgaris. Its active ingredients perform different functions:
| Component |
Role in acne treatment |
| Clindamycin phosphate 1.2% |
Topical antibiotic that reduces Cutibacterium acnes and inflammatory lesions |
| Benzoyl peroxide 5% |
Antimicrobial and keratolytic agent; reduces bacterial resistance risk associated with clindamycin |
The product is marketed under different commercial names and concentrations across jurisdictions. In the United States, the closest historical branded comparator is Benzaclin, which contains clindamycin and benzoyl peroxide but is not identical to the European Duac formulation. Product composition, regulatory status, and reimbursement therefore vary by country.
Clinical guidelines generally restrict topical antibiotics to combination use with benzoyl peroxide and limited treatment durations. The American Academy of Dermatology recommends avoiding antibiotic monotherapy because of antimicrobial-resistance concerns.[1] NICE similarly recommends combination therapy and limits prolonged antibiotic exposure.[2]
How large is the market for clindamycin and benzoyl peroxide acne products?
The addressable market is large in patient volume but mature in value. Acne affects a substantial share of adolescents and young adults, while topical products compete across prescription, pharmacy, and nonprescription channels.[3]
The main market segments are:
- Fixed-dose clindamycin and benzoyl peroxide gels such as Duac and Benzaclin.
- Benzoyl peroxide monotherapy.
- Topical retinoids, including adapalene and tretinoin.
- Fixed-dose retinoid combinations, including adapalene/benzoyl peroxide.
- Oral antibiotics for moderate inflammatory acne.
- Oral isotretinoin for severe or refractory disease.
- Cosmetic and over-the-counter acne products.
DUAC competes most directly with generic clindamycin/benzoyl peroxide gels. It also faces substitution from topical retinoid combinations. Adapalene/benzoyl peroxide products have an important strategic advantage because they avoid prolonged topical-antibiotic exposure and align more closely with antibiotic-stewardship policies.
What is the commercial history of DUAC?
DUAC was developed as a combination product to improve efficacy and reduce the resistance risk associated with clindamycin alone. Stiefel Laboratories was the principal commercial developer. GlaxoSmithKline acquired Stiefel in 2009, bringing Duac and other dermatology products into GSK’s portfolio.[4]
GSK later reduced its focus on prescription dermatology and completed the sale of its established dermatology brands to various buyers. The ownership and commercialization of Duac have varied by jurisdiction, with local marketing authorization holders and distributors often differing from the historical originator.
The commercial lifecycle has followed a standard mature-product pattern:
| Period |
Market event |
Financial effect |
| Launch and expansion |
Prescription adoption and brand establishment |
High gross margin and limited direct competition |
| Patent and regulatory maturation |
Generic development becomes feasible |
Price pressure begins |
| Generic entry |
Multiple clindamycin/benzoyl peroxide products enter |
Rapid unit-price and market-share erosion |
| Mature market |
Brand persists in selected channels |
Lower revenue, more stable residual demand |
| Long-term phase |
Substitution by antibiotic-sparing therapies |
Structural volume pressure |
GSK does not separately report Duac revenue in its public annual reports. The company reports larger business segments and product groupings rather than individual mature topical brands.[5] As a result, no reliable public Duac revenue series exists.
What is the financial trajectory for DUAC?
DUAC’s financial trajectory is best characterized as a decline from originator economics to residual branded revenue and generic-market participation.
Originator phase
Before generic erosion, the fixed-dose formulation supported premium pricing relative to its individual active ingredients. The commercial rationale included convenience, adherence, physician familiarity, and a single prescription for inflammatory acne.
Revenue during this phase would have depended on:
- Prescription volume.
- Reimbursement classification.
- Brand retention after generic substitution.
- Dermatology sales-force activity.
- Market access contracts.
- Availability of competing fixed-dose products.
Post-exclusivity phase
After regulatory and patent barriers weakened, generic manufacturers could compete on the same active ingredients and dosage form. The resulting effect is typically:
- Lower average selling price.
- Higher payer substitution.
- Reduced originator prescription share.
- Greater pharmacy-level switching.
- Lower promotional return on investment.
- More dependence on distribution and local contracting.
For a mature topical product, unit growth does not necessarily translate into revenue growth. Generic volume can increase while total category value declines because prices fall faster than demand expands.
Current financial profile
Public information supports the following conclusions:
| Financial metric |
Publicly supportable assessment |
| Standalone Duac revenue |
Not separately disclosed by GSK or historical Stiefel filings |
| Current global sales |
Not available as a consolidated public figure |
| Revenue trend |
Structurally lower than the originator period |
| Margin profile |
Lower under generic and reimbursement pressure |
| Growth driver |
Primarily market expansion or geographic distribution, not pricing power |
| Principal risk |
Substitution by generics and non-antibiotic acne regimens |
| Residual value |
Brand recognition, local formulary position, and supply continuity |
Duac may still generate commercially relevant revenue in individual countries, but its value is unlikely to be material at the level of a diversified multinational pharmaceutical company.
When did DUAC lose exclusivity?
DUAC no longer has a meaningful global exclusivity position. The relevant protection layers were limited by:
- Expiration of composition or formulation patents.
- Expiration of regulatory exclusivity.
- Availability of generic or therapeutically substitutable products.
- Local authorization of competing clindamycin/benzoyl peroxide formulations.
Patent protection is jurisdiction-specific. A patent that covered a particular formulation, manufacturing process, or use would not automatically prevent all competing products. In mature topical markets, formulation patents often have less commercial value once generic manufacturers can develop non-infringing compositions or obtain approval through an abbreviated pathway.
What patents protect DUAC?
DUAC’s original intellectual-property estate likely consisted of formulation, combination, and use-related rights rather than protection for either active ingredient.
Clindamycin and benzoyl peroxide are longstanding compounds. Their basic active-ingredient patents are not commercial barriers. Relevant historical protection would have focused on:
| Patent category |
Potential subject matter |
Current commercial relevance |
| Combination formulation |
Clindamycin with benzoyl peroxide in a topical vehicle |
Generally expired or commercially weak |
| Gel vehicle |
Stability, dispersion, viscosity, or skin delivery |
May support narrow claims |
| Manufacturing process |
Mixing, stabilization, or packaging |
Relevant only if difficult to design around |
| Method of treatment |
Treatment of acne with the combination |
Limited where method claims are expired or narrow |
| Regulatory exclusivity |
New-drug approval protection |
Expired for a mature product |
A definitive global patent count cannot be inferred from the brand name because the relevant rights differ across the United States, European Union, United Kingdom, Canada, Australia, and emerging markets.
What is the Orange Book status of DUAC?
The United States regulatory position must be distinguished from the European and UK product.
The FDA’s Drugs@FDA database and Orange Book provide the controlling records for U.S. approval, discontinued status, patent listings, and approved generic applications.[6] Duac and related clindamycin/benzoyl peroxide products have had different sponsors, strengths, and product histories. Benzaclin is the more prominent U.S. branded comparator.
The practical regulatory position is mature:
- There is no current evidence of new-molecule exclusivity.
- Any listed patents would be assessed under the specific NDA and product strength.
- Generic applicants can use an ANDA pathway if the reference product and formulation requirements are satisfied.
- A discontinued brand may still have an approved generic reference pathway if FDA records support it.
- Regulatory status cannot be transferred directly from Duac in the UK to the U.S. market.
Which companies are challenging DUAC?
The principal competitive threat comes from generic manufacturers rather than branded litigation challengers. Generic topical manufacturers can compete through:
- Abbreviated new drug applications in the United States.
- National or decentralized procedures in Europe.
- Local generic registration pathways in other markets.
- Contract manufacturing and pharmacy-distribution agreements.
The competitive field may include large generic companies, regional dermatology manufacturers, and private-label suppliers. Company-level market shares are not generally disclosed publicly for Duac as a standalone product.
Are there Paragraph IV challenges to DUAC?
No material current Paragraph IV litigation is identifiable from the public commercial record associated specifically with Duac. Paragraph IV risk is most relevant when a listed patent remains active and a generic applicant files a certification alleging that the patent is invalid, unenforceable, or not infringed.
For a mature combination topical product, the more likely pathway is ordinary generic entry after relevant patents expire or through a non-infringing formulation. The commercial significance of any historical Paragraph IV filing would depend on:
- The exact U.S. reference product.
- The patent number and expiration date.
- Whether the patent was listed in the Orange Book.
- The first-filer status of the generic applicant.
- Whether litigation triggered a 30-month stay.
- Whether the parties entered a launch settlement.
What litigation and settlement agreements affect DUAC?
No major ongoing patent litigation or high-value launch settlement has been widely associated with Duac as a standalone global asset. This distinguishes it from high-revenue small-molecule products where patent settlements can materially delay generic entry.
Potential disputes involving the product class would more likely concern:
- ANDA approval and bioequivalence.
- Formulation similarity.
- Trademark and trade dress.
- Supply and distribution contracts.
- Local reimbursement or substitution rules.
- Advertising claims for acne efficacy.
The absence of a prominent current litigation profile is consistent with a mature topical product whose principal competitive issues are price, availability, and prescribing guidelines.
How strong is the DUAC patent estate?
The patent estate is weak as a current barrier to market entry.
Strengths
- Fixed-dose delivery can create formulation-specific claim scope.
- A stable and cosmetically acceptable gel may be difficult to reproduce exactly.
- Local regulatory requirements can delay launch even without patent barriers.
- Manufacturing know-how may protect quality and shelf life.
Weaknesses
- The active ingredients are old and widely available.
- Generic manufacturers can target the same therapeutic concept.
- Formulation claims are usually narrower than active-ingredient claims.
- Benzoyl peroxide is a familiar generic ingredient with extensive manufacturing capacity.
- Topical antibiotic stewardship reduces long-term strategic value.
The commercial moat is therefore operational rather than patent-based. Reliable manufacturing, regulatory compliance, physician familiarity, and distribution are more important than exclusivity.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate. A supplier must control:
- Uniform dispersion of benzoyl peroxide.
- Clindamycin stability.
- Particle-size distribution.
- Gel viscosity and spreadability.
- Preservative performance.
- Packaging compatibility.
- Microbiological quality.
- Shelf-life specifications.
These requirements can increase development and quality-control costs, but they are not generally insurmountable for established topical manufacturers.
Packaging may also affect product performance. Airless or specialized containers can improve stability and dosing consistency, but packaging claims usually provide narrower protection than composition claims.
How does DUAC compare with competing acne products?
| Product class |
Main advantage |
Main weakness |
Competitive effect on Duac |
| Generic clindamycin/benzoyl peroxide |
Low price and familiar regimen |
Antibiotic exposure |
Direct substitution |
| Benzoyl peroxide alone |
Low cost and no antibiotic resistance from clindamycin |
Can irritate skin; less convenient for some patients |
Reduces need for fixed combination |
| Adapalene/benzoyl peroxide |
Antibiotic-sparing combination |
Irritation and slower tolerance development |
Strong guideline-aligned competitor |
| Tretinoin combinations |
Broad comedonal and inflammatory utility |
Application tolerability |
Competes in maintenance therapy |
| Oral antibiotics |
Useful in more extensive inflammatory disease |
Systemic exposure and resistance concerns |
Serves a different severity segment |
| Isotretinoin |
High efficacy in severe disease |
Monitoring and safety controls |
Not a direct substitute for routine Duac use |
DUAC retains the strongest rationale for short-term treatment of inflammatory acne when clinicians want benzoyl peroxide and topical clindamycin in one product. Its position is weaker for maintenance treatment, where non-antibiotic regimens are generally preferred.
What generic launch risks exist?
Generic entry risk is high because the product is mature and the active ingredients are inexpensive. A new entrant would face limited patent exposure but several commercial risks:
- Low reimbursement ceilings.
- Pharmacy substitution.
- Difficulty obtaining meaningful formulary share.
- Need for stable supply at low cost.
- Competition from established generic suppliers.
- Limited differentiation between approved products.
- Declining use of topical antibiotics.
A generic entrant can still succeed with a low-cost, reliable product, particularly in markets where Duac is reimbursed or where dermatologists prescribe the brand by name.
What is the geographic outlook for DUAC?
The product’s outlook differs by market.
United States
The U.S. market is price-sensitive and generic-driven. Brand value depends on the precise status of Duac, Benzaclin, and generic equivalents in FDA databases and payer formularies. Pharmacy substitution and prior authorization can sharply reduce branded share.
United Kingdom and Europe
European markets may retain branded demand through national reimbursement, dermatology prescribing, and local marketing authorization. Generic penetration varies by country. NICE guidance and antimicrobial-stewardship policies limit prolonged use.
Emerging markets
Duac may retain stronger brand recognition in countries with less aggressive generic substitution. However, local competitors can offer lower-priced clindamycin/benzoyl peroxide products, and regulatory registration requirements can differ substantially.
Key Takeaways
- DUAC is a mature clindamycin phosphate and benzoyl peroxide topical acne product.
- Its active ingredients are old, widely available, and not protected by meaningful global exclusivity.
- Generic competition is the main driver of price and market-share erosion.
- GSK and predecessor companies have not publicly disclosed standalone Duac revenue.
- The product’s financial trajectory is consistent with declining originator revenue and residual branded demand.
- The current commercial moat is based on prescribing familiarity, distribution, reimbursement, and manufacturing reliability rather than patents.
- Adapalene/benzoyl peroxide and other antibiotic-sparing regimens create long-term substitution pressure.
- No major current Paragraph IV dispute or high-value settlement is associated with Duac as a standalone global asset.
- The strongest remaining value is local and channel-specific, not global platform value.
FAQs
Is DUAC still commercially important?
DUAC remains clinically relevant in selected acne-treatment markets, but it is unlikely to be a material global revenue driver for a diversified pharmaceutical company.
Is DUAC the same as Benzaclin?
No. Both combine clindamycin and benzoyl peroxide, but their strengths, formulations, regulatory histories, and market authorizations differ.
Can generic manufacturers copy DUAC?
They can develop equivalent or therapeutically comparable products subject to local regulatory requirements. Patent protection is not expected to be a major current barrier.
Does DUAC have biosimilar competition?
No. DUAC is a synthetic small-molecule topical combination, not a biologic. Competition comes through generic-drug pathways rather than biosimilar approval pathways.
Is DUAC likely to grow in revenue?
Sustained global revenue growth is unlikely. Any growth would most likely come from geographic expansion, improved distribution, or temporary supply conditions rather than pricing power or new exclusivity.
References
- American Academy of Dermatology. (2024). Acne clinical guideline. https://www.aad.org/member/clinical-quality/guidelines/acne
- National Institute for Health and Care Excellence. (2023). Acne vulgaris: Management. NICE guideline NG198. https://www.nice.org.uk/guidance/ng198
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2023). Acne. https://www.niams.nih.gov/health-topics/acne
- GlaxoSmithKline plc. (2009). GSK completes acquisition of Stiefel Laboratories. https://www.gsk.com
- GlaxoSmithKline plc. (2024). Annual report 2023. https://www.gsk.com/investors/annual-report/
- U.S. Food and Drug Administration. (2024). Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugsatfda; https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
